Basiliximab has been tested in four randomised, double-blind, placebo-controlled studies in renal transplant recipients as an induction agent in combination with the following immunosuppressive regimens: ciclosporin for microemulsion and corticosteroids in two studies (# and # patients), ciclosporin for microemulsion, azathioprine and corticosteroids in one study (# patients), and ciclosporin for microemulsion, mycophenolate mofetil and corticosteroids in another study (# patients
ПродължавайтеEMEA0.3 EMEA0.3